dNT-1 activators, known chemically as compounds influencing NT5C, play a crucial role in modulating the functional activity of dNT-1, a key enzyme in nucleoside metabolism. These activators primarily act by either serving as substrates for dNT-1 or by modifying the cellular nucleotide environment, thereby influencing the enzyme's activity. Substrates like Adenosine, Inosine, Deoxyadenosine, Deoxyinosine, and Guanosine directly enhance dNT-1's enzymatic activity by serving as necessary components for its metabolic processes. These nucleosides, integral to purine and pyrimidine metabolism, are directly acted upon by dNT-1, facilitating effective nucleotide breakdown and recycling. Furthermore, compounds such as Dipyridamole and Ribavirin influence dNT-1's activity indirectly. Dipyridamole, by inhibiting nucleoside transport, increases the intracellular availability of substrates for dNT-1, while Ribavirin, a guanosine analog, may serve as an alternative substrate, affecting dNT-1's substrate specificity and metabolism.
Additional activators like Pentostatin, Mycophenolate Mofetil, and Allopurinol modulate the nucleotide pool within cells, indirectly enhancing the functional role of dNT-1. Pentostatin, an adenosine deaminase inhibitor, increases adenosine levels, thus potentially enhancing dNT-1's role in adenosine metabolism. Mycophenolate Mofetil, by inhibiting inosine monophosphate dehydrogenase, and Allopurinol, a xanthine oxidase inhibitor, alter purine metabolism pathways, impacting dNT-1's activity. Furthermore, Methotrexate and Fludarabine, through their roles as a dihydrofolate reductase inhibitor and a nucleotide analog, respectively, affect purine synthesis and nucleotide metabolism, thereby indirectly influencing dNT-1 activity.
Items 1 to 10 of 11 total
展示:
产品名称 | CAS # | 产品编号 | 数量 | 价格 | 应用 | 排名 |
---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | ¥451.00 ¥1455.00 ¥2369.00 ¥5528.00 ¥10481.00 | 119 | |
PMA是一种二酰基甘油类似物,可激活蛋白激酶C(PKC),后者在囊泡运输中发挥作用。激活PKC可以增强内体循环,SNX16在内体中发挥作用,从而可能提高SNX16的功能活性。 | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | ¥745.00 ¥2471.00 ¥4705.00 | 97 | |
Wortmannin是一种PI3激酶抑制剂。通过抑制PI3K,它会影响磷脂酰肌醇依赖性信号传导通路,从而改变涉及SNX16的膜运输途径,使其功能增强。 | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | ¥1715.00 ¥5810.00 | ||
莫能菌素是一种离子载体,可破坏内体pH梯度。SNX16与内体膜运输有关;改变内体pH可通过影响内体分选过程来增强SNX16的功能。 | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | ¥1083.00 ¥2821.00 ¥8462.00 ¥16111.00 | 280 | |
巴夫洛霉素A1是一种液泡型H+-ATP酶的特异性抑制剂。当内体酸化被抑制时,由于内体动力学发生变化,SNX16相关的内体分选活性会增加。 | ||||||
Chlorpromazine | 50-53-3 | sc-357313 sc-357313A | 5 g 25 g | ¥677.00 ¥1218.00 | 21 | |
氯丙嗪已知可抑制由衣藻素介导的内吞作用。通过抑制该通路,氯丙嗪可能会增加对SNX16活跃的替代内吞途径的需求,从而增强其功能。 | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | ¥982.00 | 44 | |
Dynasore 是一种动态蛋白的 GTPase 抑制剂,可阻断凝集素介导的内吞作用。这种抑制作用可能会改变通过 SNX16 所调节途径的流量,从而间接增强其活性。 | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | ¥654.00 ¥936.00 ¥1579.00 ¥2730.00 | 38 | |
诺考达唑会破坏微管,影响内体和跨高尔基体网络之间的运输,而SNX16参与其中的分类和运输,从而可能增强其功能。 | ||||||
Cytochalasin D | 22144-77-0 | sc-201442 sc-201442A | 1 mg 5 mg | ¥1636.00 ¥4987.00 | 64 | |
细胞分裂素D抑制肌动蛋白聚合。肌动蛋白在胞吞作用和囊泡运输中起着关键作用,因此抑制肌动蛋白可以间接增强SNX16的功能,改变内体动力学。 | ||||||
Pitstop 2 | 1419093-54-1 | sc-507418 | 10 mg | ¥4062.00 | ||
Pitstop 2 是一种凝集素终止子结构域抑制剂,会影响凝集素介导的内吞作用。这种抑制作用可增强 SNX16 在替代内吞途径中的功能作用。 | ||||||
ML 141 | 71203-35-5 | sc-362768 sc-362768A | 5 mg 25 mg | ¥1512.00 ¥5664.00 | 7 | |
ML141 是一种 Cdc42 抑制剂;鉴于 Cdc42 参与肌动蛋白聚合和囊泡贩运,抑制 Cdc42 可能会导致更多地依赖 SNX16 介导的途径。 |